To your point that it’s time to complete enrollment in the combo trial... You’ll likely remember from the other day the Twitter post by the recurrent GBM patient Matt Henkel from Illinois who recently received the call from UCLA that he could enter the combo trial. He was most excited to know that he was sure to now receive DCVax-L, and hoped to get Pembro, too. But was most excited to be receiving DCVax. One might also note that Henkel did not reference the treatment as an “autologous dendritic cell vaccine”, but specifically called the treatment he’d be receiving “DCVax-L.”
Market Data 
Markets 
AI
